Description: IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.
Home Page: www.ideayabio.com
IDYA Technical Analysis
7000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
650 443 6209
Officers
| Name | Title |
|---|---|
| Mr. Yujiro S. Hata | Co-Founder, CEO, Pres & Director |
| Mr. Paul A. Stone | Sr. VP, CFO & Principal Accounting Officer |
| Dr. Michael A. White Ph.D. | Sr. VP & Chief Scientific Officer |
| Dr. Jeffrey Hager Ph.D. | Co -Founder |
| Mr. Andres Ruiz Briseno CPA | VP and Head of Bus. Operations & IR |
| Mr. Jason S. Throne J.D., Esq. | Sr. VP, Gen. Counsel & Company Sec. |
| Dr. Paul A. Barsanti Ph.D. | Sr. VP & Head of Drug Discovery |
| Dr. Matthew Maurer M.D. | VP and Head of Medical Affairs & Clinical Oncology |
| Mr. Mick O'Quigley | Sr. VP of Devel. Operations |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Sr. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 4.649 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2128 |
| Price-to-Sales TTM: | 16.2851 |
| IPO Date: | 2019-05-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |